Mirada Solutions Announces Licensing and Development Agreement with UCLA for KIS -- 'Kinetic Information Systems' Software OXFORD, England, June 24 /PRNewswire-FirstCall/ -- Mirada Solutions Ltd. (a subsidiary of CTI Molecular Imaging, Inc.), leaders in software for molecular imaging, have announced today a licensing and development agreement with the Department of Medical and Molecular Pharmacology, University of California Los Angeles, for "KIS" (Kinetic Information Systems). KIS is a novel software environment which has been designed by Dr. Henry Huang and his colleagues at UCLA, for the display, analysis and simulation of pharmacokinetic and biodistribution information with PET. The software reflects many years of research and experimentation with PET, particularly for animal imaging. It will be further developed and positioned as both a freely accessible public domain analysis and educational tool for the academic community, as well as a commercial extension to Mirada's product offerings. Christian P. Behrenbruch Ph.D., President of Mirada Solutions, commented, "Dr. Huang's team has built an educational and research tool that we think has immediate applicability as part of PETNET's education program, as well as a more long-term potential. The KIS software will be developed further to become a significant component of CTI's platform for molecular imaging R&D -- primarily targeted at drug discovery and clinical trials. KIS is part of the story for 'life after FDG' as we move towards true molecular imaging applications." Dr Henry Huang said, "We are pleased to be working with Mirada and CTI to commercialize and further evolve KIS. KIS captures a lot of the strength of our group's capabilities in PET and molecular imaging. It is important that KIS will be developed not only as a generally accessible research tool that will widely benefit the academic community, but also as a technology base that is very synergistic with Mirada's own scientific developments in PET software." About Mirada Solutions: Mirada Solutions Limited, a wholly owned subsidiary of CTI Molecular Imaging, is a leading developer of software and analytical tools for medical imaging workstations, OEM imaging platforms and pharmaceutical applications. Mirada's unique products aid in better detection, diagnosis and management of disease through the application of powerful algorithms, quantification tools and image analysis. Additional information is available at http://www.mirada-solutions.com/ . About CTI Molecular Imaging: CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology used in the detection and treatment of cancer, cardiac disease and neurological disorders. Additional information is available at: http://www.ctimi.com/ . Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as "believe," "assume," "expect," "anticipate," "intend," "estimate" or similar expressions, and any other statements that necessarily depend on future events. Forward-looking statements involve a number of risks and uncertainties and there can be no assurance that any forward-looking statements will prove to be accurate. Various factors could cause actual results to differ materially from those anticipated in the forward-looking statements. CTI undertakes no obligation to update or revise any forward- looking statements. Further information regarding risks, uncertainties and other factors that could adversely affect CTI or cause actual results to differ materially from those anticipated in forward-looking statements are included in CTI's Annual Report on Form 10-K for the fiscal year ended September 30, 2003, Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. DATASOURCE: CTI Molecular Imaging, Inc.; Mirada Solutions Ltd. CONTACT: Clare F. Jones of Mirada Solutions Ltd., +1-44-1865-265-500; or Michael A. Lawless of CTI Molecular Imaging, Inc., +1-865-218-2000 Web site: http://www.ctimi.com/ http://www.mirada-solutions.com/

Copyright